[Lipids-Diagnosis and therapy in diabetes mellitus (Update 2023)]. 2023

Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
1 Medizinische Abteilung, Hanuschkrankenhaus, Wien, Österreich.

Hyper- and dyslipidemia contribute to cardiovascular morbidity and mortality in diabetic patients. Pharmacological therapy to lower LDL cholesterol has convincingly shown to reduce cardiovascular risk in diabetic patients. The present article represents the recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in diabetic patients according to current scientific evidence.

UI MeSH Term Description Entries
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D050171 Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL. Dyslipoproteinemias,Dyslipidemia,Dyslipoproteinemia
D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. HMG-CoA Reductase Inhibitor,HMG-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitor,Statin,Statins, HMG-CoA,Inhibitors, HMG-CoA Reductase,Inhibitors, Hydroxymethylglutaryl-CoA,Inhibitors, Hydroxymethylglutaryl-Coenzyme A,Statins,HMG CoA Reductase Inhibitor,HMG CoA Reductase Inhibitors,HMG-CoA Statins,Hydroxymethylglutaryl CoA Reductase Inhibitor,Hydroxymethylglutaryl CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Inhibitors,Hydroxymethylglutaryl-Coenzyme A Inhibitors,Inhibitors, HMG CoA Reductase,Inhibitors, Hydroxymethylglutaryl CoA,Inhibitors, Hydroxymethylglutaryl Coenzyme A,Inhibitors, Hydroxymethylglutaryl-CoA Reductase,Reductase Inhibitor, Hydroxymethylglutaryl-CoA,Reductase Inhibitors, HMG-CoA,Reductase Inhibitors, Hydroxymethylglutaryl-CoA,Statins, HMG CoA

Related Publications

Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
March 2024, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
March 2024, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Thomas C Wascher, and Bernhard Paulweber, and Hermann Toplak, and Christoph H Saely, and Heinz Drexel, and Bernhard Föger, and Friedrich Hoppichler, and Thomas Stulnig, and Harald Stingl, and Martin Clodi, and
January 2023, Wiener klinische Wochenschrift,
Copied contents to your clipboard!